readthroughSign in
CompanyANNXNasdaqBrisbane, CA

Annexon, Inc.

Annexon develops targeted immunotherapies that inhibit C1q-driven complement activation for neuroinflammatory diseases.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 9Latest story